tradingkey.logo
tradingkey.logo
Search

Acadia falls as rare disease therapy fails late-stage trial

ReutersSep 24, 2025 1:56 PM
facebooktwitterlinkedin
View all comments0

Shares of drugmaker Acadia Pharmaceuticals ACAD.O fall 14.8% to $20.1

Co says its experimental therapy to treat a rare metabolic condition failed to meet main goal in late-stage study

ACAD was testing treatment ACP-101 to treat hyperphagia, or feelings of intense and persistent hunger, in patients with genetic disorder called Prader-Willi syndrome

Says co does not plan to investigate therapy any further

Shares of rival drugmaker Soleno Therapeutics SLNO.O rose 12.2%

Including session's move, ACAD up 12.8% and SLNO up 44.6% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI